Registry-listed formulations

tabalumab · mesh:C575974

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

8 source entries across 8 studies. This list may not include all unresolved or historical entries.

  • LY2127399Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • LY2127399Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • LY2127399 (Tabalumab)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • LY2127399Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • TabalumabRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • LY2127399Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Tabalumab Prefilled SyringeRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Tabalumab Prefilled SyringeRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
56%(5/9)
Active Trials
0(0%)
Results Posted
180%(9 trials)
Terminated
4(44%)

Phase Distribution

Phase 2
2
22%
Phase 1
3
33%
Phase 3
4
44%

Phase Distribution

3

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(5)
Terminated(4)

Detailed Status

Completed5
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 22 (22.2%)
Phase 34 (44.4%)

Trials by Status

terminated444%
completed556%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

NCT01602224
completedphase_1

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

NCT01556438
completedphase_1

A Study of Japanese Rheumatoid Arthritis Participants

NCT01253291
completedphase_1

A Study for Japanese Participants With Rheumatoid Arthritis (RA)

NCT01253226
terminatedphase_3

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

NCT02041091
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01602224Phase 2

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

Completed
NCT01556438Phase 1

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Completed
NCT01253291Phase 1

A Study of Japanese Rheumatoid Arthritis Participants

Completed
NCT01253226Phase 1

A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Completed
NCT02041091Phase 3

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Terminated
NCT01215942Phase 3

An Open Label Study for Participants With Rheumatoid Arthritis

Terminated
NCT01576549Phase 2

A Study of LY2127399 in Rheumatoid Arthritis

Terminated
NCT01676701Phase 3

Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)

Terminated
NCT01202760Phase 3

A Rheumatoid Arthritis Study in Participants

Completed

All 9 trials loaded

Drug Details

Intervention Type
Varies by study
Molecule Type
Antibody
Total Trials
9

External References

ChEMBL
CHEMBL1743075

Names & Codes

Research Codes

Ly-2127399